Acute Lymphoid Leukemia Clinical Trial
Official title:
Phase 2 Study of Humanized CD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19) for Very High-Risk Subsets of B Cell Acute Lymphoblastic Leukemia (B-ALL)
This is a phase 2 study to evaluate humanized CD19 redirected autologous T cells (or huCART19 cells) with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia. This study is targeting pediatric and young adult patients aged 1-29 years with CD19+ B cell malignancies in newly diagnosed B-ALL patients predicted to have an exceedingly poor outcome with conventional chemotherapy, in high-risk first relapse, or and in second or greater relapse in this phase 2 trial. In addition, a second cohort will test the efficacy of huCART19 in patients with poor response to prior B cell directed engineered cell therapy.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05959720 -
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
|
||
| Recruiting |
NCT02933333 -
G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
|
Phase 4 | |
| Completed |
NCT02953730 -
The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents
|
Phase 4 | |
| Completed |
NCT02767388 -
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
|
||
| Recruiting |
NCT03610438 -
Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia
|
Phase 2 | |
| Recruiting |
NCT05792007 -
Study of the Medullary Microenvironment in Acute Childhood Leukemia
|
N/A | |
| Completed |
NCT02294552 -
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
|
Phase 2 | |
| Completed |
NCT01461538 -
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
|
Phase 2 | |
| Recruiting |
NCT04167683 -
Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
|
||
| Recruiting |
NCT05150561 -
Muscle Dysfunction in Patients With Haematological Diseases
|
||
| Active, not recruiting |
NCT04669210 -
PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT
|
Phase 2 | |
| Active, not recruiting |
NCT04013685 -
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT02345915 -
Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia
|
N/A | |
| Completed |
NCT01720264 -
Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
|
Phase 2 | |
| Not yet recruiting |
NCT02413021 -
The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens
|
Phase 1 | |
| Not yet recruiting |
NCT06427330 -
Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
|
Phase 2 | |
| Active, not recruiting |
NCT04778579 -
Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy
|
Phase 2 | |
| Recruiting |
NCT03448393 -
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
|
Phase 1 | |
| Completed |
NCT03833180 -
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
|
Phase 1 | |
| Active, not recruiting |
NCT03367299 -
Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia
|
Phase 2 |